|Day Low/High||3.38 / 3.52|
|52 Wk Low/High||2.80 / 9.95|
Has the FDA granted Cel-Sci permission to test its H1N1 flu drug in patients? Hard to say, apparently.
More work needs to be done before penciling in approval.
Risk-reward for this beaten-down stock improves as pivotal study results loom.
The flu drug company's response to government was widely expected.
One analyst uses valuation acrobatics to retain his BioCryst price target.
Higher rates of hand-foot syndrome reported in breast cancer study
The U.S. government's purchase of peramivir is not likely to yield big profits.
U.S. government seeks to stockpile small amount of peramivir for hospitalized flu patients
Flu drug maker's small but perhaps important change to its disclosures
Bulls and bears prepare for Arena Pharma's obesity drug trial results.
No government contracts for peramivir stockpiling signed yet
Biotech stocks playing in the influenza space have soared since the dawn of swine flu. Now, as the fall flu season arrives, can those stocks still perform?
Investors waiting for government to buy emergency stockpile of peramivir
Readers weigh in on Biocryst's flu drug, the forecast for Alzheimer's drugs, Allos' prognosis, and why AMAG's stock is getting pummeled.
July and August are traditionally slow months on the biotech calendar. But not this year as biotech firms, both big and small, release results from clinical trials or await FDA decisions.
Readers sound off on Discovery Labs, Micromet and BioDelivery.
Here's a look at the charts of Nasdaq stocks such as Cheesecake Factory and BioCryst.
BioCryst says that its intravenous flu drug showed positive results in study, sending its shares surging 40%.
This week, Adam Wasserman, CFO of Gold Horse International, explains this multi-faceted business group that specializes in high-growth industries in China, and reveals the company's plans within the wind power industry and what the real estate development and construction scene in China looks like right now. Also, Elsa Sung, CFO of Jiangbo Pharmaceutical, gives us the latest on the company, its recently-reported results for the third quarter of its fiscal year 2009, the acquisition of Hong Rui and how she expects the company to grow in the coming year. And, Stephanie Link, director of research for Action Alerts Plus, says this may be a time of opportunity to get in on a more pure China play - Dow Chemical. She explains why this is such an opportune time for this stock, what exciting moves Dow is making, and how you can play it. Finally, one viewer is looking for a mutual fund that encompasses all of the many Chinese Internet stocks that are growing so rapidly.
Itty bitty biotechs are big again, thanks to the H1N1 virus, cancer drug abstracts, and Vanda's recent success.
YRC Worldwide, AIG, Blockbuster, Chemed, First Energy among big market movers Friday
BioCryst Pharmaceuticals shares rise, company 'encouraged' by upcoming study data
BioCryst slides after intramuscular peramivir caused little improvement in midstage trial
Here's how to trade the swine flu as panic peaks and eases, with an emphasis on Mexican stocks.
These speculative biotech stocks could be setting up to make significant moves in the near future.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.